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Background: Pulmonary blastomas are a rare aggressive neoplasm comprising 0.25-0.5% of all primary lung tumors
and portend a poor prognosis. They display a biphasic histology with mesenchymal and epithelial components.
Historically, the term pulmonary blastoma had included both pure fetal adenocarcinomas, pleuropulmonary
blastomas as well as the classic biphasic blastomas. However recent World Health Organisation re-classifications
separated well-differentiated fetal adenocarcinomas and pleuropulmonary blastomas from the biphasic tumours.
Case presentation: We present a case of a systemically well 67-year-old Caucasian male who presented with
haemoptysis. Investigations confirmed the presence of a large right-sided lung mass and biopsy identified
non-small cell carcinoma. The resected tumour was markedly necrotic revealing a biphasic pattern. It was composed
of malignant glandular tissue with sub-nuclear vacuoles, associated with a pleomorphic stromal malignant
blastematous component, characteristic of classic biphasic pulmonary blastoma.
Conclusion: We present a case of a classic biphasic pulmonary blastoma, a rare lung cancer occurring at an earlier
age and portending to poorer prognosis than other more common lung cancers. Given the small number of cases
and recent re-classification, interpreting the published epidemiology and clinical features of this disease is difficult.
Many earlier reports may have included fetal adenocarcinomas (in particular high grade variant), which need to be
considered when discussing treatment and prognosis with newly-diagnosed patients. Much could be gained from
a central registry of individual experiences to improve our understanding of this rare lung cancer.Background
Pulmonary blastomas are a rare aggressive neoplasm
comprising 0.25-0.5% of all primary lung tumors and por-
tend a poor prognosis. Morphologically they mimic fetal
lung tissue before 4 months gestation. They display a bi-
phasic histology with mesenchymal and epithelial compo-
nents. Historically, the term pulmonary blastoma had
included both pure fetal adenocarcinomas, pleuropul-
monary blastomas as well as the classic biphasic blasto-
mas. However recent World Health Orgnisation (WHO)
reclassifications, separated well-differentiated fetal adeno-
carcinomas and pleuropulmonary blastomas from the
classic biphasic tumours. Given it’s rarity and recent re-
classification, interpreting the published epidemiology
and clinical features of this disease is challenging. We
present a case and review the literature of this rare lung
cancer.* Correspondence: robertsmyth23@gmail.com
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A 67-year-old Caucasian man presented to the out-
patient department with intermittent frank hemoptysis
of 2 months duration. He denied chest discomfort, fever,
dyspnea, weight loss or recent travel. He smoked ciga-
rettes for 80 pack years. His past medical history was
significant for ischemic heart disease and he was taking
aspirin. He was exposed to mycobacterium tuberculosis
in the distant past. He worked as a film producer and
had no known asbestos exposure. He had recently com-
menced carpentry classes. On examination he looked
well, had no clubbing, but was noted to have mild hyper-
inflation of the chest with decreased breath sounds. A
full blood count, renal and liver chemistries and resting
electrocardiograph were all normal. Sputum cytology
was also negative.
A chest radiograph (Figure 1) revealed a large, well cir-
cumscribed mass projected over the right hilum, the so
called hilum overlay sign. A subsequent computed tomog-
raphy (CT) -thorax with intra-venous contrast confirmedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Large right-sided mass with characteristic hilum
overlay sign.
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right lower lobe. It demonstrated homogenous contrast en-
hancement with no evidence of calcifications or necrosis.
The mass abutted the pleura with no sign of invasion. There
was no evidence of lymphadenopathy, pleural effusions or
osseous metastases. The liver and adrenal glands appeared
normal. A positron emission tomography-CT (PET-CT)
(Figure 2) demonstrated increased fludeoxyglucose (FDG)Figure 2 A positron emission tomography-computed tomography (PE
mass, standardized uptake value (SUV max22.1) and no evidence of nuptake within the mass with standardized uptake value
(SUV max 22.1) and no evidence of nodal involvement or
distant metastases.
A CT-guided biopsy showed a non-small cell primary
lung carcinoma with marked necrosis and poor cell dif-
ferentiation. The subtype could not be more accurately
determined. Mediastinoscopy for nodal sampling was
negative for nodal metastases. A right pneumenectomy
revealed a 9 cm large necrotic mass replacing most of the
medial and posterior segments of the right lower lobe. It
was a biphasic tumour (Figure 3a) composed of malig-
nant glandular tissue with sub-nuclear vacuoles, associ-
ated with a pleomorphic stromal malignant blastematous
component (Figure 3b).
The malignant glandular component was diffusely posi-
tive for the epithelial marker Cam 5.2 (Figure 3c), and for
thyroid transcription factor-1 (TTF-1) (Figure 3d) and
negative for vimentin, while the stromal blastematous
malignant component showed reverse expression (nega-
tive Cam5.2 and TTF-1, positive for vimentin (Figure 3e).
The protein beta-cathenin were observed in both compo-
nents (Figure 3f ). Findings were diagnostic of classic bi-
phasic pulmonary blastoma.
Discussion
Pulmonary blastomas are a rare aggressive neoplasm com-
prising 0.25-0.5% of all primary lung tumours [1]. Mor-
phologically they mimic fetal lung tissue before 4 months
gestation [2].
First described by Barnard in 1952 [3], they have
since been divided into three subgroups: classic bi-
phasic pulmonary blastoma, well-differentiated fetalT-CT) demonstrated increased fludeoxyglucose uptake within the
odal involvement or distant metastases.
Figure 3 Histological analysis of the tumour. a. Malignant glandular tissue with sub-nuclear vacuoles. b. Pleomorphic stromal malignant
blastematous component. c. The malignant glandular component was diffusely positive for the epithelial marker Cam 5.2. d. Positive for TTF-1
and negative for vimentin. e. The stromal blastematous malignant component showed reverse expression. f. The protein beta-cathenin was
observed in both components.
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blastoma- and pleuropulmonary blastoma of child-
hood. While well-differentiated fetal adenocarcinoma
contains malignant glands and benign appearing mes-
enchymal tissue and pleuropulmonary blastoma con-
tains malignant glands of embryonal appearance and
benign appearing epithelium, classic biphasic pulmon-
ary blastoma contains glands and mesenchymal tissue
that are both embryonal and malignant.
In the 1999 and 2004 WHO classifications [4,5], well-
differentiated fetal adenocarcinomas and pleuropulmon-
ary blastomas were separated from the biphasic tumours.
Classic biphasic pulmonary blastoma is now consid-
ered as part of the spectrum of sarcomatoid carcinomas.
It typically presents with cough, hemoptysis, dyspnea
or chest pain due to tumor impinging on the bronchi or
pleura. Forty percent of cases may be asymptomatic [6].The average age at diagnosis is 40 years with an increased
frequency in males (2:1) [7]. Clinical examination may re-
veal localized reduction in breath sounds or sequalae of
cigarette smoking with over 80% of cases associated with
a smoking history. Abnormalities in laboratory tests are
infrequent and non-specific. Pulmonary blastoma almost
always presents as a unilateral, large, well-circumscribed,
solitary mass on chest radiograph. Given the often, per-
ipheral nature of these tumors, tissue diagnosis by bron-
choscopy only occurs in 25% of cases [6] but they can
often be visualized on thoracic ultrasound with findings
correlating well with those seen on CT [8].
The role of PET-CT in the radiological staging of pul-
monary blastoma is unknown with our case demonstrat-
ing final pathological staging consistent with that
observed using PET-CT. Due to the challenging nature
of the histology, a preoperative diagnosis is only obtained
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clude benign conditions such as hamartoma and pleural
fibroma as well as malignant conditions such as other
primary or metastatic lung cancers.
Pulmonary blastomas are biphasic tumours that are
part of the sarcomatoid carcinoma subgroup [4], which
also include carcinosarcomas (defined as a malignant
tumour having a mixture of carcinoma- and sarcoma-
containing heterologous elements such as malignant car-
tilage, bone, or skeletal muscle) and pleomorphic carcin-
omas (similar tumour without heterologous elements),
both histologically resembling adult-type carcinomas and
sarcomas.
The epithelial component of classic biphasic blastoma
is composed of tubules of glycogen-rich, non-ciliated
cells that resemble fetal lung of pseudo-glandular stage of
lung development with sub-nuclear and supra-nuclear
glycogen vacuoles. The embryonic appearance of the
stroma is due to the small size, oval and spindle shape of
the cells, and myxoid matrix. Classically this blastema-
tous stroma does not express cytokeratins or pulmonary
markers.
Beta-catenin may play a role in tumorigenesis of clas-
sic pulmonary blastoma. Its aberrant nuclear/cytoplas-
mic localization by immunostaining has been reported
to be useful in distinguishing classic pulmonary blas-
toma from a blastomatoid variant of carcinosarcoma and
from high-grade fetal type adenocarcinomas [9].
Surgery is the optimal treatment for localized disease.
A mean survival of 33 months was reported in resected
cases compared to 2 months in those with un-resected
disease. Limited resections do better than pneumonecto-
mies [7], presumably due to less extensive tumor bur-
den. Larsen [7] reported a 16% response rate in to
chemotherapy in 43 cases of classic biphasic pulmonary
blastoma. No agent is known to be more effective than
another, but cisplatin is often used given its efficacy with
primitive tumors. Most cases have not shown a response
to radiotherapy.
Prognosis is poor with two thirds of patients dying
within 2 years and only a 16% 5-year survival. Prognosis
is determined by size of the tumor at time of diagnosis,
with tumors <5 cm doing better. Tumor metastasis and
tumor recurrence despite resection both predict a poor
prognosis. Unfortunately, 43% of tumors recur within
1 year with a propensity for sites such as brain and
mediastinum [6]. Recurrence tends to occur within 1 year
after diagnosis or not at all [7].
Conclusions
We present a case of a classic biphasic pulmonary blas-
toma, a rare lung cancer occurring at an earlier age and
portending to poorer prognosis than other more com-
mon lung cancers. Recurrence after resection is high andregular surveillance is recommended especially within
the first year. Our patient opted not to undergo adjuvant
chemotherapy and remains disease free at 23 months.
Given the small number of cases and recent re-
classification, interpreting the published epidemiology
and clinical features of this disease is difficult. Many
earlier reports may have included fetal adenocarcinomas
(in particular high grade variant), which needs to be
considered when discussing treatment and prognosis
with newly diagnosed patients. Much could be gained
from a central registry of individual experiences to im-
prove our understanding of this rare lung cancer.
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